











































Cancer, COVID-19, and the need for critique
Citation for published version:
Greco, C, Arteaga, I, Fabian-Therond, C, Llewellyn, H, Swallow, J & Viney, W 2020, 'Cancer, COVID-19,
and the need for critique', Wellcome Open Research , vol. 280, no. 5, 280.
https://doi.org/10.12688/wellcomeopenres.16404.1
Digital Object Identifier (DOI):
10.12688/wellcomeopenres.16404.1
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
OPEN LETTER
Cancer, COVID-19, and the need for critique [version 1; peer 
review: 2 approved]
Cinzia Greco 1, Ignacia Arteaga2, Clara Fabian-Therond3, Henry Llewellyn4, 
Julia Swallow5, William Viney6
1Centre for the History of Science Technology and Medicine (CHSTM), University of Manchester, Manchester, M13 9PL, UK 
2Department of Social Anthropology, University of Cambridge, Cambridge, CB2 3RF, UK 
3Department of Anthropology, University College London, London, WC1H 0BW, UK 
4UCL Division of Psychiatry, University College London, London, W1T 7NF, UK 
5Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9LD, UK 
6Department of Anthropology, Goldsmiths, University of London, London, SE14 6NW, UK 
First published: 27 Nov 2020, 5:280  
https://doi.org/10.12688/wellcomeopenres.16404.1





In this open letter we examine the implications of the coronavirus 
disease 2019 (COVID-19) pandemic for cancer research and care from 
the point of view of the social studies of science, technology, and 
medicine. We discuss how the pandemic has disrupted several aspects 
of cancer care, underscoring the fragmentation of institutional 
arrangements, the malleable priorities in cancer research, and the 
changing promises of therapeutic innovation. We argue for the critical 
relevance of qualitative social sciences in cancer research during the 
pandemic despite the difficulties of immersive kinds of fieldwork. 
Social science research can help understand the ongoing, situated and 
lived impact of the pandemic, as well as fully underline its socially 
stratified consequences. We outline the risk that limiting and 
prioritising research activities according to their immediate clinical 
outcomes might have in the relational and longitudinal understanding 
of cancer practices in the UK. Finally, we alert against potential 
distortions that a “covidization” of cancer research might entail, 
arguing for the need to maintain a critical point of view on the 
pandemic.
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Disclaimer
The views expressed in this article are those of the author(s). 
Publication in Wellcome Open Research does not imply endorse-
ment by Wellcome.
The entanglements between cancer care and 
COVID-19: A multi-layered disruption
The coronavirus disease 2019 (COVID-19) pandemic has 
abruptly altered the lives of millions and caused major disrup-
tions to those classified as the most vulnerable segments of the 
population by the UK Government, including patients living 
with cancer. Millions of elective operations postponed (Sample, 
2020) pathways altered (see Cancer Research UK news article), 
waiting times increased, screening programs suspended (Maringe 
et al., 2020), medical personnel under significant stress (see 
BMA mental health wellbing report). There was a significant 
upheaval to the ordinary activities of NHS trusts, professional 
bodies and structures already enduring austerity and manageri-
alisation policies. Such upheaval had marked consequences for 
cancer care. Since the start of the pandemic in the UK, several 
articles have brought forward the testimonies of patients whose 
treatments have been interrupted or delayed or who were 
alerted that they would have not found a place in ICU had they 
contracted COVID-19 (Hughes, 2020).
Modelling approaches to statistically estimating the disruption 
brought by the pandemic are focusing mainly on excess mor-
tality and life-years lost, something that it is in itself difficult 
to ascertain within the current time-frame. Sud et al. (2020), 
focusing on mortality derived from diagnostic delays, alert 
that “[u]nlike acute pathologies, such as stroke and myocar-
dial infarction, the true excess mortality due to COVID-19-
related disruption to cancer pathways will not be fully evident 
for 10 years or longer”. The risk in this perspective is that we 
would not be able to understand the disruption until well after 
the pandemic, when data on mortality become clear. Further, 
those distal statistical approaches make it difficult to have a full 
understanding of how and for whom cancer services have been 
disrupted.
In the meantime, longitudinal observational work could shed 
some light on the multiple tensions that are informing clinical 
dynamics, yet ethnographic work on cancer contexts has also 
been interrupted. Ethnography offers insights into different 
timescales, experiences, and points of view. Patients, relatives 
and healthcare professionals who experience proximal disruption 
are required to deal with novel situations and improvise 
care-work practices within changing terrains. Yet, disruptions 
are emerging across the cancer care continuum and are not 
limited to pausing screening and diagnostic delays, but also 
involve patients already in treatment and those in follow-up 
care. Those who are affected by advanced cancer often rely on 
clinical trials to access potentially life-lengthening treatments. 
Because of their bodily vulnerability, this segment of patients is 
particularly impacted by the suspension of research on cancer and 
of clinical trials. However, we must keep in mind that some of 
the features that are considered to be disruptions for the patients 
might not be perceived as such by the medical professionals, and 
vice-versa. The difficulty of in-person consultations, in some 
cases substituted by telephone and/or online exchanges, as well as 
not being able to have a relative to come along, have a different 
impact for patients than for clinical professionals. Understand-
ing the different ways in which cancer care has been impacted 
by the pandemic therefore requires to look at an ample range of 
alterations, both immediate and long-term, to cancer care. Such 
an understanding – a project for which the social sciences are 
pivotal – is greatly needed in order to plan supporting mechanisms 
for the patients and the full reactivation of services.
This open letter is the result of an online workshop organised 
in late September 2020 on the mutual implications between 
cancer care and COVID-19, involving six researchers whose 
scholarship concerns the practices, experiences and ideologies 
informing the fields of cancer in the UK.
The fragmentation of cancer care
In addition to the disruption to NHS services, charities working 
both on cancer care and cancer research have experienced 
significant difficulties since the beginning of the pandemic, with 
income yielded from donations dropping suddenly and ensuing 
restructurations of their own operations (see Cancer Research 
UK blog on funding cuts). Medical charities in the UK not only 
fund basic and population-based cancer research, but they also 
offer guidance and support to patients with cancer both outside 
and inside the NHS, also delivering pan-cancer rehabilitation 
services across the country (e.g. Macmillan Cancer Support). 
The ongoing crisis that cancer charities are facing reveals a 
significant paradox. Most charitable organisations have developed 
either to cover areas that had limited public support (e.g. Marie 
Curie provides palliative care) or to cover areas from which the 
public services have retreated, such as the case of psycho-social 
support.
Due to the pandemic, even a government guided by a party 
historically hostile to public spending has taken some excep-
tional policies to alleviate bottlenecks and improve access to 
treatments in a healthcare service overwhelmed by demand. 
This has shown the possibility, and arguably the necessity, for 
centralising healthcare services and resources under public 
control to deal both with peaks in the number of cases, and the 
continued provision of ordinary healthcare needs. However, 
a significant part of the care that patients rely on is managed 
through charities, which because of their financing model, legal 
status, and organisational structure, are difficult to centralise 
under public control. The risk is that even if the government 
decides to allocate the resources necessary to avoid major 
disruptions to cancer services during a public health crisis, an 
important part of the current offer of cancer care in the UK 
might be significantly affected.
COVID-19 is revealing the fragmentation in cancer care 
that is located at the intersection between private and public 
management, charity and industry, also evidencing the persistent 
effect of austerity policies in the healthcare domain. In this 
fragmented landscape, some patients find comfort and support in 
less institutionalised contexts, such as neighbourhood, friendship 
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or confessional groups. However, the requirement for social 
distancing during the pandemic has also altered the availability 
of these forms of help, thus worsening the quality of life of 
cancer patients who have needed to shield to minimize the risk 
of contracting the virus suffering from already compromised 
immune-defence mechanisms.
In this context, it is urgent that we study the real-time 
changes materialising prospectively so we can both shed light on 
changes in quick time (see Vindrola Padros et al., 2020) as well 
as develop rich and sustained scholarship throughout the pan-
demic. Such analysis better shows how forces and structures 
which might appear intractable were not always inevitable, as 
much long-term ethnographic work attests (Biehl & Locke, 2017).
(Re)shaping research practices during COVID-19: 
Challenges and possibilities
Social studies of science, technology and medicine continue to 
play a vital role in understanding interactions between biology, 
subjects, and environments. Eschewing simple and reductive 
accounts, they have tackled social worlds in their complexity 
and considered the mutual constitution of these domains and 
entities. Recent scholarship has explored how novel understand-
ings of biology reshape our worlds, organise our societies, and 
inform how we understand ourselves (Wahlberg, 2018). Other 
contributions have mapped the social effects of biomedi-
cine, informing changing perceptions of the body, normative 
definitions of what is considered to be a desirable behaviour, and 
public entitlements to health and care (Lock & Nguyen, 2011; 
Petryna, 2002). Moreover, many social science scholars have 
delved into the lived experiences of those seeking care, unpack-
ing the particular relationships through which people affected 
by conditions withstand disease-related suffering and sometimes 
find relief (Das, 2015). This scholarship has also developed 
critical lenses on emergence, provisionality, revolutionary 
change and stabilisation in science, technology and care (Keating 
& Cambrosio, 2003). In the field of oncology, social science 
disciplines have played and continue to have important roles in 
understanding relations among experts and publics, perceptions 
of risk, experiences of the cancerous body, inequalities in access 
to standard and experimental treatments, professional practices, 
informal care work, and the involvement of diverse publics in 
cancer-related research (Arteaga, 2019; Arteaga Pérez, 2020; 
Day et al., 2016; Greco, 2016; Greco, 2019; Kerr & 
Cunningham-Burley, 2015; Kerr et al., 2018; Llewellyn 
et al., 2018; Llewellyn & Higgs, 2020; Swallow et al., 2020; 
Therond et al., 2020). Through an array of ethnographic research 
practices including interviews, observation, participatory tech-
niques, and archival research, social sciences scholarship has 
contributed to our understandings of the promises, ambivalences, 
complexities and difficulties within the biomedical field from 
the perspective of different stakeholders, including patients, 
caregivers, medical professionals, scientists, and interested 
publics. Over recent months each of us - as social scientists, 
members of families, and civic actors - have found ourselves 
dislocated from our assumptions and routines pre-COVID-19. 
This visceral sense of dislocation contributes significant social 
and professional challenges. However, it also provides a new 
critical space to reflect, amongst other things, on how we are 
able to conduct and communicate our research in this time of 
COVID-19.
As large portions of our social life have been redirected 
online, the social sciences are also in the process of adapting 
methods and theoretical frameworks to better understand the 
challenges posed by the pandemic to those affected by cancer 
either personally or professionally. The discussion emerging 
from the workshop demonstrated how, as social scientists, our 
current research practices have not only been constrained by the 
pandemic but also reshaped. As ethnographers, we are all too 
aware that barriers to the “on-the-ground,” in person, physically-
situated component of our work – momentarily or for longer 
periods – poses risks to research practice. Online and remote 
research, while offering safer access to the communities with 
whom we work, cannot fully grasp the material and contextual 
nuances that inform people’s everyday efforts; it changes the 
relational dynamics between the ethnographer and participant, 
and the opportunities for participant-observation in field sites 
as a core ethnographic endeavour.
Part of the difficulties we are experiencing in relation to the 
current constraints of immersive and situated research methods 
in social research parallel those of medical professionals and 
patients, whose own relations have also been redrawn. For 
medical professionals, virtual approaches bring challenges to 
usual techniques of assessing, supporting, responding to and 
caring for patients. For patients, daily routines have been 
radically disrupted, care provision has been redefined with 
cancelled appointments and procedures, and virtual follow-up 
clinics. All are subject to increased uncertainties in their 
lives and work, coupled with on-going emotional labour that 
characterises provisional and highly precarious knowledge, policy 
and practice about the pandemic.
Moreover, online recruitment strategies in social science research 
can privilege participants who tend to have more resources 
and time at their disposal, inevitably skewing the range of 
lived realities we are able to encounter as researchers, given 
that internet access reflects wider social and structural inequali-
ties. As with social scientists, clinical research coordinators 
must grapple with the sample bias that the COVID-19 pandemic 
might pose, considering their own mandates to protect patients 
from the intrusion of research into clinical pathways, which 
might stand for an essential component of care. Whilst clinical 
experiences and practices are changing, our methodologies start 
reflecting and recording those changes.
This pandemic, while sudden and harsh, is not the cause of all 
the current problems in healthcare settings, but a contributor, 
catalyst and powerful amplifier. The pandemic has exacerbated 
existing fragilities and reactivated old fault-lines that research 
on healthcare services and oncology has already shown 
(Arteaga et al., 2019). With this in mind, we think it is impor-
tant to resist the temptation to divide the reality in a pre- and 
post-COVID-19 and instead look to critically reflect on the 
role of social science and qualitative research specifically for 
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addressing these challenges whilst also reflecting on the 
emergence of alternative knowledge-making practices.
The covidization of research: the role of qualitative 
social science research
Aware of the continuity between the clinical, financial and 
political difficulties already existing in the National Health 
Service before March 2020, we are cautious to not fall into 
the “covidization” of all scientific research (Pai, 2020). With 
restrictions to social life still in place and the number of cases 
increasing day by day, the pandemic seems to be, if not the 
only, certainly the dominant interpretative framework to analyse 
the present, especially in the biomedical field. Embedded at 
various levels, from funding, research portfolio management, 
research ethics, study sponsorship, capacity and capability 
assessments; and through the discretionary decisions of clinical 
teams, this framework has had significant impacts on the devel-
opment of research infrastructures and consequently the kinds 
of knowledge that are produced. A recent consensus-building 
paper produced by Cancer Core Europe (van de Haar et al., 
2020) suggests to “reduce preclinical research activities to a 
bare minimum” and “stop patient inclusion for clinical studies 
or trials requiring additional actions and/or visits” (667) – this, 
in practice, makes translational cancer research an exception. 
Moreover, in a demonstration of “ethical variability” in clinical 
care (Petryna, 2005), the authors argue for the need for the 
selective “adjustment” (that is, de-escalation) of anticancer 
therapeutic regimes during the pandemic. This involves the 
hypothesis that the de-escalated treatments could be normal-
ised post-pandemic if the clinical outcomes are not inferior to 
those of the pre-pandemic treatments. As a prime example of 
the covidization of research, the published roadmap claims that 
“[t]he COVID-19 pandemic may offer a unique window of 
opportunity for retrospective trials, assessing the non-inferiority 
of de-escalated treatment regimens, which may be difficult to 
perform under normal conditions for ethical reasons” (670).
The redefinition of research activities during the pandemic 
intersects with and reinforces pre-existing professional, 
institutional, disciplinary and epistemological hierarchies. 
Whether pre-approved studies are funded by the National 
Institute of Health Research (NIHR; the largest funder of health 
and care research in the UK) or not, frameworks such as the 
NIHR Restart determine what is considered “urgent” and 
hence of essential value (defined as “patient benefit” and health 
delivery “cost-efficacy”). NIHR Restart then sifts through 
particular studies in relation to present and potential risks, 
prioritising certain (clinical, measurable) approaches while 
stalling others (social, critical) where value is difficult to 
estimate.
Although such logics of urgency and priority are inevitable 
and important in contexts of radically compromised capacity, 
we are keen to advocate for guiding principles that accommo-
date the kinds of critical social science work outlined above, 
which examines and bears witness to the social consequences 
of disease and care, and the ongoing articulation of ethical 
frameworks across a variegated society. In particular, we have in 
mind approaches that offer perspectives of a qualitative nature 
and those that reside beyond the limits of the clinic, which 
nevertheless offer an essential contribution to the understanding 
of the social impact and personal stakes that the pandemic has 
brought onto healthcare services and people’s everyday lives. If 
COVID-19 has surfaced the UK’s enduring health inequalities 
into public awareness, then the organisational streamlining and 
prioritisation of clinical and biomedical research within the 
NHS risks, paradoxically, sidelining the social scientific research 
that can bear witness to the wider social dynamics that are core 
to COVID-19’s uneven effects. At stake in this “covidization” 
of research is thus both a broader and more nuanced under-
standing of the pandemic and its effects and the displacement of 
important work in other arenas that are not explicitly deemed 
“COVID-related” (Pai, 2020). Indeed, just as the pandemic 
exposes and is exacerbated by socio-cultural, economic and 
political disparities, it is critical that qualitative researchers are 
enabled to document and better understand the social effects 
of COVID-19 on cancer treatment and care across and beyond 
the UK.
Looking at the future: Intersections between 
COVID-19 and the promise and practice of 
personalised cancer medicine
Important innovations in cancer treatments have been linked 
to the identification of specific biological markers, allowing 
for targeted therapies for specific subgroups of patients. It is 
this kind of stratification practices that are behind the promises 
of what is commonly called “personalised” medicine. Yet, 
the COVID-19 pandemic has, in many ways, redirected the 
“circulation of scientific promises” in personalised medicine 
that have tended to be attached to oncology and rare diseases 
(Sturdy, 2017:31).
We know that the impact of COVID-19 on cancer research 
communities is profound, as funding and public/private invest-
ment is squeezed, and human and non-human resources are 
re-routed to help tackle the virus’s effect on society and 
citizens (see Cancer Research UK Open Letter to researchers). 
We have seen how laboratory closures, as a result of the national 
lockdown, slowed down scientific progress thus exacerbating 
any mismatch between upstream promises in cancer research 
and their downstream translation into clinical care (see Can-
cer Research UK researchers lockdown experience survey). As 
Genome UK: The Future of Healthcare (Department of Health 
and Social Care, 2020:19) outlined, some of the most exciting 
developments in early detection involve interval observational 
studies that track circulating tumour DNA (ctDNA). However, 
sample collection for such studies are not priorities and 
involve patients in follow-up; their hospital appointments have 
been cancelled in recent months. Moreover, even before the 
COVID-19 pandemic access to clinical trials could be patchy 
and lacking in patient diversity in places across and beyond the 
UK (Kerr & Cunningham-Burley, 2015). During the initial 
months of the pandemic clinical trial recruitment ground to 
a halt in the UK which meant for many patients a missed 
window of opportunity to access potentially life-extending 
drugs.
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The current challenge of conducting social science research in 
the clinical settings means examining the broader social impact 
of the pandemic on the practices of personalisation are yet to 
fully materialise, teasing out how the pandemic intensifies micro 
and macro-level asymmetries of personalised cancer care. As 
patients navigate an even more uncertain landscape of complex 
care, the pandemic reminds us of the ongoing, and in fact urgent 
need to scrutinize the meaning of personalisation. Indeed, the 
virus continues to demonstrate how a truly personalised approach 
in healthcare should not be confined to the biological aspects of 
treatments but must also consider the needs of the patient from a 
holistic point of view (Day et al., 2016; Prainsack, 2018).
A third “C”: The need for critique
While seeking to acknowledge the impact of the pandemic 
on research and care infrastructures around cancer, we invite 
caution towards totalising tendencies. The risk of covidizing cancer 
resembles the #ForgottenC, an online hashtag becoming popular 
in online platforms among charities and other advocacy groups. 
Remembering cancer during the pandemic presumes to know 
and thus recall cancer as a figure being forgotten. We want to call 
attention to work carried out in clinical and non-clinical contexts 
that highlights the diverse and unequal resources afforded to 
people using health services in the UK. We encourage our 
colleagues to look at cancer as a biosocial phenomenon rather 
than limiting it to the simplified narrative portrayed as part of 
charitable fundraising efforts.
Reckoning with a #ForgottenC is to do critical work with 
longer histories of managerialism, streamlining and efficiency 
saving in the context of public sector austerity, privatisation, 
biotech and pharma profiteering, and the degradation of hospital 
estates. How we remember one C should put to work another: 
“critique”. Critical work involves considerations of our own 
privileges, biases and limitations, especially our dependencies 
on the private wealth of charitable organisations, conditions 
what social science can do within a pandemic. It involves, again, 
reckoning with our dependencies, antagonisms, and entangle-
ments with biomedicine. Building on our expertise as social 
science scholars in the field of cancer, we sought to outline 
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Department of Psychology and Ergonomics, Technical University of Berlin, Berlin, Germany 
I enjoyed reading the open letter “Cancer, Covid-19, and the need for critique”. It is a very well-
written piece contributing to discussions about the entanglements between Covid-19, cancer care 
and social science research. The open letter addresses the impact of the pandemic on cancer care, 
on patient's lives and points out that this current “moment of crisis” reveals a fragmentation in 
cancer care that already existed before. 
 
However, the main argument, as I understand it, is a call for the importance of - underestimated 
and neglected within the field cancer research in times of the pandemic - qualitative social science 
research. 
 
Overall, I think this argument, and in particular its development from the concrete example of the 
fragmentation of cancer care to the need for critical social scientific debate, works. 
 
However, it might also be this structure that leaves me as a reader missing clarity as to what the 
authors' main intention or main argument is. 
 
For instance, the description of fragmentation could be elaborated on in more detail, if this is an 
example for why and how social scientist can contribute to critical research on cancer care. 
Otherwise, in the end, it is still unclear how this exactly becomes relevant or critical in practice. At 
the same time, I was wondering, if this reasoning for social sciences as a primarily critical form of 
knowledge production - without elaborating on its contributions in more detail - reinforces an 
image of a distanced “critique from outside”. Following Latour (2014) this form of deconstructive 
critique from social sciences is not effective anymore in order to contribute to current social 
questions. But this might be a follow-up question and not so vital to the letter. 
 
By the same token, I was wondering why the authors did not refer to some more of their own 
work in order to clarify abovementioned fragmentation – this would additionally support the 
argument that research should not be divided into pre- and post- COVID-19 research. 
Also, the examples in the open letter are based on a specific national cancer care context. For me, 
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as a non-UK researcher, it would help to know more about the division into public and private 
health care to understand the argument. 
 
On the other hand, I feel that the part on research practices during COVID-19 beyond the 
description of the current difficulties is too general and only loosely tied to the other parts. I think 
it could gain if it would be tied to either concrete options and examples of how the authors 
currently work, or to the question of fragmentation (e.g. along the lines of: does the use of digital 
counselling in cancer care versus personal counselling lead to another variant of fragmentation?). 
 
Furthermore, I would like to know more about the context of the workshop that led to this open 
letter. Why did you meet up and organize a workshop? What was your initial question? And how 
did you end up with this open letter? 
 
All these comments can be addressed relatively easy and I hope that they help to strengthen and 
clarify the important argument in this text.
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This open letter is rich and thoughtful. It offers, for one thing, a review of the ways in which the 
cancer care industry and its actors all along the line - including its frontline physicians and patients 
– have been impacted by the COVID-19 pandemic. Here, the letter points to accounts of patients 
whose treatments have been disrupted and whose status within healthcare has changed: from 
those heavily dependent on the system to those too ill to be treated should they contract severe 
COVID. 
 
At the same time, the letter points out the dangerous potential for attribution errors during a 
pandemic, noting that the so-called “covidization” of cancer cuts two ways: in its implication that 
COVID-19 has actively disrupted cancer research and therapy, it notes the novelty of a once-in-a-
generation health event on all aspects of the “regular” system of the cancer care industry . But it 
also introduces the risk that too much attention to this specialness will paper over what are 
actually longer-standing continuities, forces or factors attributable to causes outside of COVID-19. 
 
But both of these themes are subordinate to what I take to be the letter’s main argument: that 
those who study cancer from the perspective of the social studies of science, technology and 
medicine ought to be considered critical players in this discussion – as critical, in fact, as any of the 
other knowledge-making actors in cancer care – because the factors that they are uniquely 
equipped to deal with, the biosocial, cultural, economic, political, etc, are just as fundamental to 
the creation of cancer as any other. In this, the authors are calling for recognition that disease is 
not just a clinical creation and that as a result the factors relevant to understanding, signifying and 
managing a disease cannot be limited only to those who experience it clinically. 
 
The authors underscore this point in a variety of useful ways, and I think the argument works by 
and large, though it remains a question to me whether this is something that the authors feel is 
specific only to cancer or whether there discussion here is actually more radical, that when we 
acknowledge, as we publicly do, that medicine and health are more than just clinical entities, it 
makes little sense to prioritise clinical entities as those suited to define its significance. 
 
Given how potentially important the authors indicate the role of the social scientist is, it feels a bit 
of a let down that they do not indicate more precisely what it is that the presence of social 
scientists in cancer’s inner knowledge-making circle might yield. The language they use to 
describe their role is remarkable for its passivity. Reseachers “bear witness to” or are “enable[ed]” 
to “document and better understand”. This leaves a hole at the veritable center of the argument: 
what is it, besides watching and documenting, that social scientists are able to contribute? The 
translation from arguing the case from a matter of academic necessity to arguing it as a matter of 
real-time, real world necessity is not fully described here, even though the real world significance 
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I wonder if perhaps this omission is a translational one: the difficulty of describing one’s 
significance in terms other than those internal to one’s own work is well known. And if so, I 
wonder whether the letter is not otherwise troubled by this translation, or perhaps by the 
artefactual remains of what were clearly wide-ranging and dynamic conversations had at the 
conference in September. Among other things, the discussion of the difficulties of social scientific 
research in a pandemic feels very specific, yet the letter is not necessarily otherwise specifically 
about the difficulties particularly attendant with social science research in a pandemic exactly. The 
situation is similar with the discussion of the NIHR: a very specific reference that feels out of 
keeping with some of the more thematic points made in the letter, even if it used to make a point 
about research priorities. And the discussion of personalized medicine, while interesting and 
thoughtful, also seems awkwardly bent toward the matter at hand. The reference to Steve Sturdy’s 
work here, indeed, feels a bit of a red herring: I read that work as a rich provocation about how to 
(re)signify personalized medicine. But this section doesn’t follow through on Sturdy’s notions of 
bioetch’s “promissory economy” and instead almost seems to double down on a slightly more 
facile notion of personalized medicine that, given the theoretical richness of their account in other 
places, seems just out of place. 
 
Both of the above can be addressed relatively easily and are not so vital to the letter's main 
argument. What should be addressed, I think, is the uncertainty attached to the notion of 
covidization. Initially, covidization seems primed to refer in quite a facile way to research costs. 
The referenced text focuses on researchers attracted to study COVID whose loss aggrieves the 
community of researchers they’ve left; whose help, for lack of expertise, is actually not helpful to 
those they’ve joined; and who thus add to a cacophony of scientific voices rather than becoming a 
part of a single cohesive sensibility about how to think about and what to do about COVID. This 
rather reductive view (of covidization but also of scientific research, for that matter) feels out of 
place, and the examples the authors include of the covidization of cancer don’t clarify how their 
meaning of the term relates to this one. 
 
It seems to me that covidization for the authors ultimately seems to signify something to do with 
an inability to strike a balance between the novelty of the pandemic, at least in our lifetimes, and 
its non-novelty, both as a historical phenomenon and as a prism onto healthcare in real time. Does 
COVID represent a change in kind or a change in degree? 
 
If this reading is right, then we are left with some uncertainty about the status of the letter. Is it 
suggesting something about the attendant and specific difficulties of cancer and COVID, of cancer 
as a covidized disease, and therefore the need for social scientific contributions? If so, does this 
contradict the richness of the definition of covidization that the authors provide? Or are the 
authors saying that now, as at all times, social scientists need to be involved in the study of 
cancer? And if so, does this mean that their intonation of COVID here is too strong? Some 
resolution to this conceptual difficulty would be in order. If, for example, it is that COVID has 
exacerbated and/or laid bare for us what is already true about cancer, then this is certainly worth 
saying. Whatever their position, greater clarity would help a great deal to bring out the really 
important message that this letter contains.
 
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
 
Page 11 of 12
Wellcome Open Research 2020, 5:280 Last updated: 26 JAN 2021
Yes
Are all factual statements correct, and are statements and arguments made adequately 
supported by citations?
Yes
Is the Open Letter written in accessible language?
Partly
Where applicable, are recommendations and next steps explained clearly for others to 
follow?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: History of health and healthcare.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
 
Page 12 of 12
Wellcome Open Research 2020, 5:280 Last updated: 26 JAN 2021
